ORIC PHARMACEUTICALS, INC. Payments of Stock Issuance Costs
ORIC PHARMACEUTICALS, INC. (ORIC) reported Payments of Stock Issuance Costs of $993.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $993.00K.
- ORIC PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- ORIC PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $1.74M.
- ORIC PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2025 was $2.40M, a 1326.79% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2024 was $168.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $993.00K 10-Q · filed 2026-08-03 | $993.00K derived: sum of 3 quarters · filed 2026-08-03 | $2.73M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $993.00K 10-Q · filed 2026-05-04 | $993.00K derived: sum of 2 quarters · filed 2026-05-04 | $2.73M derived: sum of 3 quarters · filed 2026-05-04 | $3.39M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.74M derived: sum of 2 quarters · filed 2026-02-23 | $2.40M derived: sum of 3 quarters · filed 2026-08-03 | $2.40M 10-K · filed 2026-02-23 |
| 2025-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.40M derived: sum of 2 quarters · filed 2026-08-03 | $2.40M 10-Q · filed 2025-11-13 | $2.40M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $656.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $656.00K 10-Q · filed 2026-08-03 | $656.00K derived: sum of 3 quarters · filed 2026-08-03 | $656.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $0.00 derived: sum of 3 quarters · filed 2026-05-04 | $0.00 derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $168.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $168.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $168.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $168.00K 10-Q · filed 2025-05-05 | |||
| 2019-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $121.00K derived: sum of 2 quarters · filed 2020-11-05 | $136.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $15.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $15.00K 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |